Sort
39,280 grants matching “leukemia”
Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia
$300,000Dale J Christensen · Oncotide Pharmaceuticals, Inc. · R41 · FY2012 · CA
Phamacological modulation of epigenetic changes in AML
$300,000Guido Marcucci · Ohio State University · R01 · FY2010 · CA
Involvement of Survivin in the Development of PML
$300,000Luis Del Valle · Temple Univ Of The Commonwealth · R01 · FY2008 · NS
Novel Nanodrug Delivery System to Optimize Dose of Oncology Drugs
$300,000Anjani Jha · Maa Laboratories, Inc. · R43 · FY2017 · CA
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$300,000Bethany Foch Grant · Kytopen Corp · R44 · FY2021 · AI
HTLV-1 & Cellular Factors in Neuroinflammatory Disease
$300,000Brian Wigdahl · Drexel University · R01 · FY2006 · CA
Effects of germline GATA3 variants on ALL somatic genomics and prognosis in multi-ethnic populations
$299,999Jun J. Yang · St. Jude Children'S Research Hospital · R56 · FY2022 · CA
Biologic for the Treatment of High Risk B Cell Acute Lymphoblastic Leukemia
$299,999Xianmei Meng · Elf Zone, Inc. · R43 · FY2017 · CA
Tunable Polymer-Graphene Oxide Composite for Single Cell Analysis of Breast Cancer CTCs & CSCs
$299,999Sunitha Nagrath · University Of Michigan At Ann Arbor · R56 · FY2016 · CA
EAGER: Biomanufacturing: Optimizing the Isolation, Transfection, and Expansion of CAR-T Cells with Modified PES Membranes
$299,999Jacob Elmer · Villanova University · · FY2016 · ENG
Feasibility of predicting AML response to induction chemotherapy
$299,999Paul Thomas Henderson · Accelerated Medical Diagnostics, Llc · R43 · FY2017 · CA
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
$299,998Eric J Brown · Atrin Pharmaceuticals · R41 · FY2016 · CA
Protein purification by selective coacervation
$299,998Paul L Dubin · University Of Massachusetts Amherst · · FY2010 · ENG
Dendritic cell therapy for GvHD
$299,989Katherine L Knight · Hasentech, Inc. · R41 · FY2024 · AI
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
$299,975W. Andy Tao · Tymora Analytical Operations, Llc · R41 · FY2020 · GM
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML
$299,975Hong Yu Li · Synactix Pharmaceuticals, Inc. · R41 · FY2018 · CA
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes
$299,972Jeffrey S Miller · University Of Minnesota · P01 · FY2016 · CA
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes
$299,972Jeffrey S Miller · University Of Minnesota · P01 · FY2018 · CA
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes
$299,972Jeffrey S Miller · University Of Minnesota · P01 · FY2017 · CA
Proteomic differentiation of leukemia cells based on multiplexed arrays and mass
$299,967W. Andy Tao · Tymora Analytical Operations, Llc · R41 · FY2013 · GM
Fanconi Anemia and HPV Transformation
$299,947Susanne Irmtraud Wells · Cincinnati Childrens Hosp Med Ctr · R01 · FY2009 · CA
Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase
$299,939Amanda M Schalk · Enzyme By Design, Inc. · R43 · FY2019 · CA
Sensitive Single Cell PhosphoCount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia
$299,931Jeffrey S King · Virogenomics Biodevelopment, Inc. · R43 · FY2016 · CA
Chimeric Ligands for Induced Proximity (CLIP) platform for targeted proteome editing and upregulation of antigen presentation
$299,921Luiz Miguel Quinn Camargo · Ubiquitx, Inc. · R41 · FY2024 · AI
Pre-Targeting of AML Cells and Subsequent Delivery of High Payloads of Radionuclides
$299,920Joel Berniac · Akrivis Technologies, Llc · N43 · FY2015 · CA